Examples of monographs that appeared in USP 39–NF 34 include Acamprosate Calcium (new), Abacavir and Lamivudine Tablets (new), Acetazolamide, Acetazolamide for Injection, Hypromellose (incorporated via the Second Supplement), and various excipients including Cholesterol.
: Chapter provides specific limits for the amount of elemental impurities (like lead, mercury, and arsenic) allowed in drug products. usp 39 pdf
Patent disputes, generic drug challenges, or liability cases may require proof of a monograph standard on a specific date. Examples of monographs that appeared in USP 39–NF
In USP 38–NF 33, the omission of General Chapter <231> Heavy Metals was published with an official date of December 1, 2015. Cross‑references to <231> were removed from individual monographs in USP 38 and USP 39 and following publications, with delayed implementation on January 1, 2018. USP 39 thus represents the edition where the heavy metals phase‑out was fully documented and the elemental impurities framework was finalized in preparation for its 2018 implementation. In USP 38–NF 33, the omission of General
These describe validated testing procedures, such as chromatography, dissolution, and microbial limits.
The USP 39 is not merely a book; it is a legally recognized book of public pharmacopeial standards. It is often combined with the , creating a comprehensive document that defines:
Rounding rules for analytical calculations and standard tolerances for purity percentages. 2. Key General Chapters ( to )